2. Search Result
Search Result
Results for "

organ transplant

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

4

Peptides

7

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135005A
    Biliverdin
    1 Publications Verification

    		 Endogenous Metabolite Inflammation/Immunology
    Biliverdin, a tetrapyrrolic pigment, is a product of heme catabolism. Heme is broken down into Biliverdin and carbon monoxide and iron by heme oxidase. Biliverdin is then quickly broken down to bilirubin by Biliverdin reductase. Biliverdin can mediate the protective effects of HO-1 in many disease models including IRI and organ transplantation. Biliverdin exhibits anti-mutagenic, an antioxidant, anti-inflammatory, and immunosuppressant properties .
    Biliverdin
  • HY-P99315
    Ruplizumab

    BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

    		 TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ruplizumab
  • HY-P99152
    Muromonab

    Muromanab-CD3

    		 CD3 Interleukin Related IFNAR Inflammation/Immunology Cancer
    Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
    Muromonab
  • HY-153128
    DOCK2-IN-1

    		DOCK Drug Derivative Inflammation/Immunology
    DOCK2-IN-1 (Compound 3) is an analog of CPYPP (HY-110100) and a DOCK2 inhibitor (IC50 = 19.1 μM). DOCK2-IN-1 binds to the DHR-2 domain of DOCK2 and inhibits its mediated Rac guanine nucleotide exchange factor activity. DOCK2-IN-1 blocks chemokine receptor- and antigen receptor-mediated activation of Rac in lymphocytes. DOCK2-IN-1 significantly inhibits chemotaxis and T cell activation. DOCK2-IN-1 can be used in the research of transplant rejection and organ-specific autoimmune diseases .
    DOCK2-IN-1
  • HY-110217
    BMS-566419

    		IMPDH Inflammation/Immunology
    BMS-566419 is an orally active IMPDH inhibitor with an IC50 of 91 nM against human IMPDH I and 68 nM against human IMPDH II. BMS-566419 exerts anti-heart transplant rejection and anti-renal fibrosis effects, and inhibits the expression of MCP-1, TGF-β1 as well as antibody production. BMS-566419 can be used in research on renal fibrosis and organ transplantation .
    BMS-566419
  • HY-118530
    Bucillamine
    2 Publications Verification

    SA96; Thiobutarit

    		 VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine
  • HY-P990025
    Empasiprubart

    ARGX-117

    		 Complement System Inflammation/Immunology
    Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
    Empasiprubart
  • HY-P99257
    Bleselumab

    ASKP 1240

    		 TNF Receptor Inflammation/Immunology
    Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
    Bleselumab
  • HY-110086
    RWJ 50271

    		Integrin Inflammation/Immunology
    RWJ 50271 is an selective and orally active inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells). RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion .
    RWJ 50271
  • HY-14921
    Elsibucol

    		Integrin Transmembrane Glycoprotein Cardiovascular Disease Inflammation/Immunology
    Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury .
    Elsibucol
  • HY-171888
    BI-9740

    		Cathepsin Elastase Inflammation/Immunology
    BI-9740 is an orally active and selective cathepsin C (CatC) inhibitor, with an IC50 of 0.6 nM in mice and 2.6 nM in rats. BI-9740 can inhibit the production of active neutrophil elastase. Additionally, BI-9740 is capable of reducing the activities of neutrophil elastase and cathepsin G in the bone marrow of rats, alleviating pathological damage to grafts after heart transplantation, shortening the reperfusion time, and improving left ventricular function. BI-9740 can be used in research related to organ transplantation .
    BI-9740
  • HY-118917
    VX-148

    		IMPDH Inflammation/Immunology
    VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
    VX-148
  • HY-N12396
    Cyclosporin U

    		Others Inflammation/Immunology
    Cyclosporin U (SMP0V32C6L) is an cytostatic agent that plays an important role in preventing rejection of transplanted organs .
    Cyclosporin U
  • HY-P991153
    Potravitug

    		Virus Protease Infection
    Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
    Potravitug
  • HY-136622
    A-420983

    		Src
    A-420983 is a potent, orally active inhibitor of Lck and can be used in studies involving animal models of delayed-type hypersensitivity and organ transplant rejection .
    A-420983
  • HY-18228
    CP-352664

    		JAK Inflammation/Immunology
    CP-352664 is a JAK inhibitor. CP-352664 has a inhibitoinhibits JAK3 with an EC50 value of 210 nM. CP-352664 is promising for research of organ transplant rejection and autoimmune disorders such as rheumatoid arthritis .
    CP-352664
  • HY-177700
    Immunosuppressant-2

    		Others Inflammation/Immunology
    Immunosuppressant-2 (Example 21) is an orally active immunosuppressant. Immunosuppressant-2 significantly reduces the number of circulating lymphocytes. Immunosuppressant-2 can be used for research on various autoimmune diseases and organ transplant rejection .
    Immunosuppressant-2
  • HY-P5767
    Fibrinogen γ-chain (117-133)

    		Integrin Cardiovascular Disease
    Fibrinogen γ-chain (117-133) is a selective intercellular adhesion molecule-1 (ICAM-1) inhibitor (IC50≈20-40 μg/mL). Fibrinogen γ-chain (117-133) blocks fibrinogen-mediated monocyte-endothelial adhesion. Fibrinogen γ-chain (117-133) is promising for research of thrombo-inflammatory diseases (e.g., atherosclerosis, organ transplant rejection) .
    Fibrinogen γ-chain (117-133)
  • HY-P5888
    PKCε inhibitor peptide,myristoylated

    Myr‐PKCɛ-

    		 PKC Inflammation/Immunology
    PKCε inhibitor peptide,myristoylated (Myr-PKCε-) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    PKCε inhibitor peptide,myristoylated
  • HY-118530R
    Bucillamine (Standard)

    SA96 (Standard); Thiobutarit (Standard)

    		 Reference Standards VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (Standard) is the analytical standard of Bucillamine. This product is intended for research and analytical applications. Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine (Standard)
  • HY-119681
    YM 11124

    		Others Inflammation/Immunology
    YM 11124 is an orally active selective immunosuppressive agent. YM 11124 can inhibit cell-mediated immune responses (type IV allergic reactions, such as delayed-type hypersensitivity and allogenic skin graft rejection) and type III allergic reactions (such as passive Arthus reaction). YM 11124 has no effect on type I, type II allergic reactions or acute inflammation. YM 11124 can be used in research related to organ transplantation and immune hypersensitivity .
    YM 11124
  • HY-P5877
    ɛPKC(85–92),Myristoylated

    		PKC Inflammation/Immunology
    PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    ɛPKC(85–92),Myristoylated
  • HY-P992154
    Ricefidase

    KJ-103

    		 Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Infection Inflammation/Immunology
    Ricefidase (KJ-103) is a recombinant human immunoglobulin G-degrading enzyme. Ricefidase efficiently cleaves human IgG at the hinge region. Ricefidase rapidly reduces IgG levels. Ricefidase has low immunogenicity and clears AAV neutralizing antibodies. Ricefidase is applicable to research related to desensitization of all IgG subclasses and improvement of the suitability of AAV-based gene therapy .
    Ricefidase

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: